Lymph node metastasis as a favorable prognostic factor in metastatic urothelial carcinoma with histological variants treated with pembrolizumab: a retrospective multicentric study (YUSHIMA study-04)

20260 citationsJournal Article

Authors

Ichiro Yonese · Tokyo Metropolitan Komagome Hospital

Fumitaka Koga · Tokyo Metropolitan Komagome Hospital

Masahiro Toide · Tokyo Metropolitan Komagome Hospital

Yuya Maezawa · Tsuchiura Kyodo General Hospital

Kensaku Ishihara · Soka Municipal Hospital

Naoki Inoue · JA Toride Medical Center

Kenji Tanabe

Abstract

The presence of LNM may be a HV-UC-specific prognostic factor of a favorable outcome in patients with mUC receiving pembrolizumab as second-line or later therapy.

Topics & Keywords

Bladder and Urothelial Cancer Treatments Renal cell carcinoma treatment Cancer Immunotherapy and Biomarkers

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Japanese Journal of Clinical Oncology

DOI: 10.1093/jjco/hyag041

Field-Weighted Citation Impact: 0.00